NCT04265872 2026-02-12
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
Baylor Research Institute
Phase EARLY_PHASE1 Recruiting
Clinical Trials
4 trialsNCT06637306 2025-03-26
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase EARLY_PHASE1 Recruiting
NCT03514121 2024-11-22
FPA150-001
Five Prime Therapeutics, Inc.
Phase EARLY_PHASE1 Terminated
NCT03197389 2021-05-19
Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.
Universitaire Ziekenhuizen KU Leuven
Phase EARLY_PHASE1 Completed